← Back to Screener
Kymera Therapeutics, Inc. Common Stock (KYMR)
Price$86.14
Favorite Metrics
Price vs S&P 500 (26W)54.12%
Price vs S&P 500 (4W)6.64%
Market Capitalization$7.27B
All Metrics
Book Value / Share (Quarterly)$19.42
P/TBV (Annual)2.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.75%
Cash Flow / Share (Quarterly)$-2.88
Price vs S&P 500 (YTD)11.74%
Net Profit Margin (TTM)-794.06%
EPS (TTM)$-3.68
10-Day Avg Trading Volume0.50M
EPS Excl Extra (TTM)$-3.68
Revenue Growth (5Y)2.87%
EPS (Annual)$-3.69
ROI (Annual)-19.67%
Net Profit Margin (5Y Avg)-384.96%
Cash / Share (Quarterly)$10.43
Revenue Growth QoQ (YoY)-61.18%
ROA (Last FY)-17.86%
Revenue Growth TTM (YoY)-16.70%
EBITD / Share (TTM)$-4.04
ROE (5Y Avg)-27.42%
Operating Margin (TTM)-891.10%
Cash Flow / Share (Annual)$-2.88
P/B Ratio4.60x
P/B Ratio (Quarterly)3.89x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)176.29x
Net Interest Coverage (TTM)-1072.50x
ROA (TTM)-25.45%
EPS Incl Extra (Annual)$-3.69
Current Ratio (Annual)10.47x
Quick Ratio (Quarterly)10.19x
3-Month Avg Trading Volume0.90M
52-Week Price Return249.98%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.13
P/S Ratio (Annual)185.31x
Asset Turnover (Annual)0.02x
52-Week High$103.00
Operating Margin (5Y Avg)-427.98%
EPS Excl Extra (Annual)$-3.69
CapEx CAGR (5Y)-30.75%
26-Week Price Return58.11%
Quick Ratio (Annual)10.19x
13-Week Price Return21.77%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.47x
Enterprise Value$6,912.438
Revenue / Share Growth (5Y)-9.51%
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)24.94%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-794.04%
Cash / Share (Annual)$10.43
3-Month Return Std Dev41.92%
Net Income / Employee (TTM)$-1
ROE (Last FY)-19.71%
EPS Basic Excl Extra (Annual)$-3.69
Receivables Turnover (TTM)66.41x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.68
Receivables Turnover (Annual)4.78x
ROI (TTM)-28.98%
P/S Ratio (TTM)185.31x
Pretax Margin (5Y Avg)-384.96%
Revenue / Share (Annual)$0.46
Tangible BV / Share (Annual)$8.91
Price vs S&P 500 (52W)220.15%
Year-to-Date Return14.38%
5-Day Price Return1.89%
EPS Normalized (Annual)$-3.69
ROA (5Y Avg)-21.70%
Net Profit Margin (Annual)-794.04%
Month-to-Date Return6.86%
Cash Flow / Share (TTM)$-2.82
EBITD / Share (Annual)$-4.04
Operating Margin (Annual)-891.07%
LT Debt / Equity (Annual)0.25x
ROI (5Y Avg)-27.28%
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-3.68
P/TBV (Quarterly)2.80x
P/B Ratio (Annual)3.89x
Pretax Margin (TTM)-794.06%
Book Value / Share (Annual)$19.42
Price vs S&P 500 (13W)21.08%
Beta2.22x
P/FCF (Annual)91.94x
Revenue / Share (TTM)$0.44
ROE (TTM)-29.07%
52-Week Low$24.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.31
4.31
4.31
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KYMRKymera Therapeutics, Inc. Common Stock | 185.31x | -16.70% | — | — | $86.14 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule medicines targeting STAT6, TYK2, and IRAK4—proteins with known disease-causing biology that remain undrugged or inadequately treated with existing therapies. The company uses proprietary technologies to overcome limitations that have previously prevented effective drug development against these targets. Its disease-agnostic approach aims to generate a differentiated pipeline addressing multiple therapeutic areas with these validated biological targets.